نتائج البحث - April Killikelly

  • يعرض 1 - 6 نتائج من 6
تنقيح النتائج
  1. 1
    Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus

    Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus حسب April Killikelly, Masaru Kanekiyo, Barney S. Graham

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses

    Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses حسب Phaedra Davis, Joshua Montroy, Bryna Warshawsky, Elissa M. Abrams, Lucy Coward, April Killikelly

    منشور في 2025
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection

    Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection حسب Elissa M. Abrams, Paméla Doyon-Plourde, Phaedra Davis, Liza Lee, Abbas Rahal, Nicholas Brousseau, Winnie Siu, April Killikelly

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Structural Basis of Cyclophilin B Binding by the Calnexin/Calreticulin P-domain

    Structural Basis of Cyclophilin B Binding by the Calnexin/Calreticulin P-domain حسب Guennadi Kozlov, Sara Bastos‐Aristizabal, Pekka Määttänen, Angelika Rosenauer, Fenglin Zheng, April Killikelly, Jean‐François Trempe, David Y. Thomas, Kalle Gehring

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

    Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants حسب Gebremedhin Beedemariam Gebretekle, Man Wah Yeung, Raphael Ximenes, Alexandra Cernat, Alison E. Simmons, April Killikelly, Winnie Siu, Ellen Rafferty, Nicholas Brousseau, Matthew Tunis, Ashleigh R. Tuite

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

    Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera حسب Joan O. Ngwuta, Man Chen, Kayvon Modjarrad, Michael Joyce, Masaru Kanekiyo, Azad Kumar, Hadi M. Yassine, Syed M. Moin, April Killikelly, Gwo‐Yu Chuang, Aliaksandr Druz, Ivelin S. Georgiev, Emily J. Rundlet, Mallika Sastry, Guillaume B. E. Stewart-Jones, Yongping Yang, Baoshan Zhang, Martha Nason, Cristina Capella, Mark E. Peeples, Julie E. Ledgerwood, Jason S. McLellan, Peter D. Kwong, Barney S. Graham

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: